Emory’s Ticiana Leal, MD, Says Rise in Druggable Targets Boosts Importance of Biomarker Testing in NSCLC
AJMC,
It’s well known that targeted therapy has demonstrated improved survival in clinical trials of patients with non-small cell…
It’s well known that targeted therapy has demonstrated improved survival in clinical trials of patients with non-small cell…
Promoting safe and effective cancer care delivery warrants consideration of factors beyond the care provided in the clinic.
Abstract In the era of precision medicine, timely cancer genotyping is necessary to guide treatment and glean valuable…
July 23, 2021 13 min read Source/Disclosures Published by: Source: Gutierrez ME, et al.
By Clinical Content Hub Among cancer types, lung cancer is the most frequently diagnosed, having accounted for 11.4% of the…
(Image courtesy Pixabay) [ Editor's note: This story originally was published by Real Clear Health.
AsiaNet 87867 【東京2021年2月3日PR Newswire】ガーダントヘルスジャパン株式会社(本社:東京、代表取締役:シムランジット・シン、塚田アンドレアス信一)は、2021年1月28日に全血検体を用いた固形がんの包括的ゲノムプロファイル検査…
TOKYO, Feb. 3 -- Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East
By: PR Newswire Association LLC. - 03 Feb 2021 A comprehensive genomic profiling test utilizing blood samples from patients…
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East
TOKYO, Feb. 3, 2021 /PRNewswire/ -- Japan, an affiliate of Guardant Health Asia, Middle East
TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East
03-Feb-2021 Intellasia | PR Newswire Asia | 5:41 PM A comprehensive genomic profiling test utilizing blood samples from…
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
A comprehensive genomic profiling test utilizing blood samples from patients with advanced solid tumors TOKYO, Feb.
Data Shows First-Line Testing with Guardant Health Liquid Biopsy Uncovers 23.6 Percent More Actionable Mutations Than with…
REDWOOD CITY, Calif.--(Business Wire)-- Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive…
Data Shows First-Line Testing with Guardant Health Liquid Biopsy Uncovers 23.6 Percent More Actionable Mutations Than with…
Data Shows First-Line Testing with Guardant Health Liquid Biopsy Uncovers 23.6 Percent More Actionable Mutations Than with…
Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients…
Data Shows First-Line Testing with Guardant Health Liquid Biopsy Uncovers 23.6 Percent More Actionable Mutations Than with…
Data Shows First-Line Testing with Guardant Health Liquid Biopsy Uncovers 23.6 Percent More Actionable Mutations Than with…
The campaign encourages oncologists to stop, test, and wait for complete biomarker testing results before starting initial…
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent 1 of patients at increased…
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent 1 of patients at increased…
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent 1 of patients at increased…
/ EIN News / -- Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent 1 of…
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent1 of patients at increased…
(GLOBE NEWSWIRE) -- Guardant Health, Inc. ( GH ) has launched the Clear Your View campaign to raise awareness of the important…
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent 1 of patients at increased…
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent1 of patients at increased…
So-called “liquid biopsies” — noninvasive tests used to evaluate blood for cancer cells or DNA — have been refined extensively…
Summary Guardant Health Inc. focuses on precision oncology. In Q1, Guardant Health noted 9,521 clinical tests, which represents…
Published results of a liquid biopsy study in lung cancer patients could lead oncologists to prioritize blood-based genomic…
(GLOBE NEWSWIRE) -- Guardant Health, Inc. (NASDAQ:GH), announced that the positive results from the NILE study, a head-to-head…